Bharat Biotech’s intranasal vaccine – Update

August 16, 2022

Bharat Biotech recently sought approval for its intranasal Covid vaccine candidate, BBV154, as two-dose vaccine as well as booster dose. It submitted data from Phase 3 clinical trials of BBV154 to seek approval.

Highlights:

The heterologous booster infers that, third or subsequent dose of the vaccine is not similar to its primary dose.
Usually, primary doses include two shots.
According to Bharat Biotech, BBV154 is stable at 2-8 degrees Celsius. It is safe, well-tolerated and immunogenic under controlled clinical trials.

About BBV154:

BBV154 is an intranasal vaccine, that have capability to produce local antibodies in upper respiratory tract. These are capable of reducing infection and transmission.
To evaluate BBV154 as primary dose and booster dose, two separate & simultaneous clinical trials were conducted.
Primary dose Phase III trials were conducted on more than 3000 individuals, to test its safety, and immunogenicity. Trials were conducted across 14 sites in India.
On the other hand, studies on heterologous booster dose were conducted on over 800 individuals.
This vaccine has been formulated to allow its delivery through nasal.
Nasal delivery system is cost-effective for low and middle-income countries.
BBV154 nasal vaccine has been developed by Bharat Biotech, in association with the Washington University.

Bharat Biotech International Limited (BBIL):

BBIL is headquartered in Hyderabad. The company is engaged in discovering drug, developing drug, manufacturing vaccines, pharmaceuticals and health care products. It was established in 1996.

« Previous Post Next Post »